Article Sidebar

pdf
Date Published: 24/09/2024
Abstract Views: 39
Views pdf: 2
DOI: https://doi.org/10.51298/vmj.v542i2.11102
Issue
Vol. 542 No. 2 (2024)
Section
Các bài báo
How to Cite
Lê, Q. T., & Lê, T. T. H. (2024). EFFECTIVENESS AND SAFETY OF TREATMENT REGIMEN CONTAINING MOXIFLOXACIN IN FIRST TREATMENT OF HELICOBACTER PYLORI. Vietnam Medical Journal, 542(2). https://doi.org/10.51298/vmj.v542i2.11102

EFFECTIVENESS AND SAFETY OF TREATMENT REGIMEN CONTAINING MOXIFLOXACIN IN FIRST TREATMENT OF HELICOBACTER PYLORI

Quốc Tuấn Lê, Thị Thu Hiền Lê

Main Article Content

Abstract

Objective: To evaluate the effectiveness and safety of a treatment regimen containing Moxifloxacin in the first treatment of H. pylori. Subjects and methods: Prospective study on 205 patients treated to eliminate H.pylori with AMR and AMBR, at Clinic 103 Cam Khe, Phu Tho Province from January 2022 to January 2023. Results: Mean age was 42.56±10.67 years. Antral gastritis and atrophic gastritis account for the highest rates. There were 53.2% of patients treated with three drugs containing Moxifloxacin and 46.8% of patients receiving four drugs containing bismuth. The eradication rate in both groups was similar in ITT and PP and reached over 90.0%. Common side effects are abdominal discomfort and nausea. The AMR group had fewer side effects than the AMBR group. Treatment compliance of patients in the AMR group was higher than that in the AMBR group. Conclusion: The three-drug regimen containing Moxifloxacin is effective and safe in the treatment of H.pylori eradication.

Article Details

Keywords

Moxifloxacin, Helicobacter pylori (H. pylori), effectiveness, safety

References

Sumaira Khadim et al (2023),The efficacy of moxifloxacin-based triple-therapy in first-line treatment of Helicobacter pylori infection in Pakistan: randomized controlled trials. Arch Med Sci Civil Dis;8(1):31-37
2. Ahmed Mansur Kadhim et al (2023), Treatment of Helicobacter Pylori Infections using Moxifloxacin-Triple Therapy Compared to Standard Triple and Quadruple Therapies Iraqi J Pharm Sci, 32 (1).
3. Mohammed Hussien Ahmed (2020), Moxifloxacin Based Triple Therapy as Alternative to Standard Therapy in Helicobacter Pylori Eradication DOI: 10.2174/ 2211352518999200925154501.
4. Yuan Wenzhen et al (2009), Moxifloxacin-Based Triple Therapy Versus Clarithromycin-Based Triple Therapy for First-Line Treatment of Helicobacter pylori Infection: A Meta-Analysis of Randomized Controlled Trials, Inter Med 48: 2069-2076, 2009 DOI: 10.2169/internalmedicine.48.2344.
5. Thung I, et al (2016): the global emergence of Helicobacter pylori antibiotic resistance. Aliment Pharmacol Ther. 2016;43:514-33. doi: 10.1111/.